These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32199147)

  • 1. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction.
    de Alwis N; Beard S; Mangwiro YT; Binder NK; Kaitu'u-Lino TJ; Brownfoot FC; Tong S; Hannan NJ
    Pregnancy Hypertens; 2020 Apr; 20():83-91. PubMed ID: 32199147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.
    Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Kaitu'u-Lino TJ
    BMC Pregnancy Childbirth; 2016 May; 16():117. PubMed ID: 27207105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia.
    Brownfoot FC; Tong S; Hannan NJ; Binder NK; Walker SP; Cannon P; Hastie R; Onda K; Kaitu'u-Lino TJ
    Hypertension; 2015 Sep; 66(3):687-97; discussion 445. PubMed ID: 26222708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.
    Kaitu'u-Lino TJ; Brownfoot FC; Beard S; Cannon P; Hastie R; Nguyen TV; Binder NK; Tong S; Hannan NJ
    PLoS One; 2018; 13(2):e0188845. PubMed ID: 29466360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
    Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia.
    Onda K; Tong S; Nakahara A; Kondo M; Monchusho H; Hirano T; Kaitu'u-Lino T; Beard S; Binder N; Tuohey L; Brownfoot F; Hannan NJ
    Hypertension; 2015 Apr; 65(4):855-62. PubMed ID: 25667213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ
    Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome.
    Hastie R; Ye L; Hannan NJ; Brownfoot FC; Cannon P; Nguyen V; Tong S; Kaitu'u-Lino TJ
    Pregnancy Hypertens; 2018 Oct; 14():125-130. PubMed ID: 30527099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment.
    Hannan NJ; Brownfoot FC; Cannon P; Deo M; Beard S; Nguyen TV; Palmer KR; Tong S; Kaitu'u-Lino TJ
    Sci Rep; 2017 May; 7(1):1819. PubMed ID: 28500309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide.
    Yang JC; Huang F; Wu CJ; Chen YC; Lu TH; Hsieh CH
    Inflamm Res; 2012 May; 61(5):485-91. PubMed ID: 22245985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fetal endothelium dysfunction is associated with circulating maternal levels of sE-selectin, sVCAM1, and sFlt-1 during pre-eclampsia.
    Veas CJ; Aguilera VC; Muñoz IJ; Gallardo VI; Miguel PL; González MA; Lamperti LI; Escudero CA; Aguayo CR
    J Matern Fetal Neonatal Med; 2011 Nov; 24(11):1371-7. PubMed ID: 21381877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia.
    Hannan NJ; Binder NK; Beard S; Nguyen TV; Kaitu'u-Lino TJ; Tong S
    PLoS One; 2018; 13(4):e0187082. PubMed ID: 29641523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine Mitigates the Production of 8-Isoprostane and Improves Vascular Dysfunction: Implications for Treating Preeclampsia.
    Rahman RA; Murthi P; Singh H; Gurungsinghe S; Leaw B; Mockler JC; Lim R; Wallace EM
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial.
    Ahmed A; Williams DJ; Cheed V; Middleton LJ; Ahmad S; Wang K; Vince AT; Hewett P; Spencer K; Khan KS; Daniels JP;
    BJOG; 2020 Mar; 127(4):478-488. PubMed ID: 31715077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction.
    Onda K; Tong S; Beard S; Binder N; Muto M; Senadheera SN; Parry L; Dilworth M; Renshall L; Brownfoot F; Hastie R; Tuohey L; Palmer K; Hirano T; Ikawa M; Kaitu'u-Lino T; Hannan NJ
    Hypertension; 2017 Mar; 69(3):457-468. PubMed ID: 28115513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.
    Palmer KR; Kaitu'u-Lino TJ; Hastie R; Hannan NJ; Ye L; Binder N; Cannon P; Tuohey L; Johns TG; Shub A; Tong S
    Hypertension; 2015 Dec; 66(6):1251-9. PubMed ID: 26416849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia.
    Saad AF; Kechichian T; Yin H; Sbrana E; Longo M; Wen M; Tamayo E; Hankins GD; Saade GR; Costantine MM
    Reprod Sci; 2014 Jan; 21(1):138-45. PubMed ID: 23749761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paeoniflorin alleviates endothelial dysfunction caused by overexpression of soluble fms-like tyrosine kinase 1 and soluble endoglin in preeclampsia via VEGFA upregulation.
    Zhang J; Hua W; Zhao X; Yang F; Guo T; Zhang J; Zheng X; Liang W
    Biosci Biotechnol Biochem; 2021 Mar; 85(4):814-823. PubMed ID: 33590855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mZD7349 peptide-conjugated PLGA nanoparticles directed against VCAM-1 for targeted delivery of simvastatin to restore dysfunctional HUVECs.
    Imanparast F; Faramarzi MA; Vatannejad A; Paknejad M; Deiham B; Kobarfard F; Amani A; Doosti M
    Microvasc Res; 2017 Jul; 112():14-19. PubMed ID: 28161429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells.
    Brownfoot FC; Hannan N; Onda K; Tong S; Kaitu'u-Lino T
    Placenta; 2014 Sep; 35(9):724-31. PubMed ID: 25043692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.